BR112015018335A2 - Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas - Google Patents

Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas

Info

Publication number
BR112015018335A2
BR112015018335A2 BR112015018335A BR112015018335A BR112015018335A2 BR 112015018335 A2 BR112015018335 A2 BR 112015018335A2 BR 112015018335 A BR112015018335 A BR 112015018335A BR 112015018335 A BR112015018335 A BR 112015018335A BR 112015018335 A2 BR112015018335 A2 BR 112015018335A2
Authority
BR
Brazil
Prior art keywords
seq
nutritional compositions
protein
compositions containing
peptide component
Prior art date
Application number
BR112015018335A
Other languages
English (en)
Inventor
A F Van Tol Eric
Hondmann Dirk
Gross Gabriele
H Schoemaker Marieke
Tim Lambers Teartse
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of BR112015018335A2 publication Critical patent/BR112015018335A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

COMPOSIÇÕES NUTRITIVAS CONTENDO UM COMPONENTE PEPTÍDICO COM PROPRIEDADES ANTI-INFLAMATÓRIAS E USOS DAS MESMAS. A presente invenção refere-se a composições nutritivas contendo uma fonte equivalente à proteína, em que 20% a 80% da fonte equivalente à proteína compreende um componente peptídico contendo SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, e SEQ ID NO 63; e 20% a 80% da fonte equivalente a proteína compreende uma proteína intacta, uma proteína parcialmente hidrolisada ou combinações das mesmas. A descrição refere-se adicionalmente a métodos para reduzir a resposta inflamatória e/ou produção de citocinas pró-inflamatórias, isto é, Interleucina-17, pela administração dessas composições nutritivas a um paciente alvo.
BR112015018335A 2013-03-15 2014-03-11 Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas BR112015018335A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/833,094 US8889633B2 (en) 2013-03-15 2013-03-15 Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
PCT/US2014/023608 WO2014150558A1 (en) 2013-03-15 2014-03-11 Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof

Publications (1)

Publication Number Publication Date
BR112015018335A2 true BR112015018335A2 (pt) 2017-08-22

Family

ID=50483515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018335A BR112015018335A2 (pt) 2013-03-15 2014-03-11 Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas

Country Status (18)

Country Link
US (2) US8889633B2 (pt)
EP (1) EP2983531B1 (pt)
CN (1) CN105072928B (pt)
AR (1) AR095332A1 (pt)
AU (1) AU2014237014B2 (pt)
BR (1) BR112015018335A2 (pt)
CA (1) CA2905799C (pt)
ES (1) ES2736313T3 (pt)
HK (1) HK1216976A1 (pt)
MX (1) MX365415B (pt)
MY (1) MY172218A (pt)
NZ (1) NZ710020A (pt)
PE (1) PE20151978A1 (pt)
PH (1) PH12015502071B1 (pt)
RU (1) RU2015140269A (pt)
SG (1) SG11201505689PA (pt)
TW (1) TW201521603A (pt)
WO (1) WO2014150558A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US20170020950A1 (en) * 2015-07-23 2017-01-26 Mead Johnson Nutrition Company Methods for modulating kinases
JP2018537441A (ja) * 2015-11-09 2018-12-20 エム・ジェイ・エヌ ユー．エス． ホールディングス リミテッド ライアビリティー カンパニー Ｌｇｇ並びに食品酪酸塩および／または内因性酪酸塩の形成を刺激するための化合物を含む栄養組成物
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
EP3397078A1 (en) 2015-12-28 2018-11-07 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
CA3060243A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US20220000132A1 (en) 2019-02-22 2022-01-06 Aquero Canada Ltd. Fortified milk compositions and their processes of preparation
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
GB2608587A (en) * 2021-06-25 2023-01-11 Mjn Us Holdings Llc Use of extensively hydrolysed protein

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
US4016260A (en) 1974-07-22 1977-04-05 Toyama Chemical Co., Ltd. Novel polypeptide produced by pseudomonas
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A0 (fi) 1989-08-28 1990-08-17 Milupa Ag Protein-, peptid- och aminosyrablandningar med optimerad aminosyrasammansaettning samt deras anvaendning foer framstaellning av naering foer prematur- och dibarn samt av tillsatser till modersmjoelk.
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
EP1787532A3 (en) 1991-01-24 2010-03-31 Martek Biosciences Corporation Microbial oil mixtures and uses thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
GB9310472D0 (en) 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
IT1277964B1 (it) 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
AU3666497A (en) 1996-07-17 1998-02-09 Nutracorp Scientific, Inc. Appetite suppression
KR100221124B1 (ko) 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
DE69930464D1 (de) 1999-12-30 2006-05-11 Kerry Group Services Ltd Aufbaupräparat, das Kohlenhydrat- und Peptidmaterial enthält und sein Gebrauch als Energieergänzung nach oder während körperlicher Übung oder als metabolischer Nährstoff für die orale Verabreichung
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
TWI268138B (en) 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
KR20070069221A (ko) 2000-06-28 2007-07-02 후지 니혼 세이토 코퍼레이션 신규한 이눌린 합성효소 및 이를 이용하는 이눌린의제조방법
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
WO2002032231A1 (en) 2000-10-19 2002-04-25 Edens, Luppo Protein hydrolysates
US20050019372A1 (en) 2001-07-10 2005-01-27 Barbara E Corkey Modified-fat nutritional products useful preventing or treating obesity
RU2292155C2 (ru) 2001-07-18 2007-01-27 ДСМ Ай Пи ЭССЕТС Б.В. Способ гидролиза молочных белков
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
JP3816921B2 (ja) 2001-11-21 2006-08-30 森永乳業株式会社 アンジオテンシン変換酵素阻害作用を有する新規ペプチド
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP1509609B1 (en) 2002-06-04 2015-04-22 DSM IP Assets B.V. Protein hydrolysate rich in tripeptides
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
US7648957B2 (en) 2002-09-04 2010-01-19 Dsm Ip Assets B.V. Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
KR20050044758A (ko) 2002-11-29 2005-05-12 모리나가 뉴교 가부시키가이샤 시스테인 프로테아제 억제제
ATE490323T1 (de) 2002-12-29 2010-12-15 Toudai Tlo Ltd Adiponektin-rezeptor und dafür kodierendes gen
JP2006525003A (ja) 2003-05-05 2006-11-09 ユニリーバー・ナームローゼ・ベンノートシヤープ Ｉｐｐおよび／またはｖｐｐを含む加水分解カゼイン製品
ES2746173T3 (es) 2003-09-23 2020-03-05 Dsm Ip Assets Bv Uso de endoproteasas específicas para prolina para hidrolizar péptidos y proteínas
SI1733730T1 (sl) 2003-10-24 2008-12-31 Nutricia Nv Imunomodulirajoči oligosaharidi
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
WO2005072056A2 (en) 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
EP1751179A4 (en) 2004-03-01 2009-03-25 Peptera Pharmaceuticals Ltd PEPTIDES DERIVED FROM THE CASEIN AND THEIR THERAPEUTIC USES
EP1753443A1 (en) 2004-05-27 2007-02-21 Campina Nederland Holding B.V. Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR100560127B1 (ko) 2004-09-04 2006-03-13 한국기초과학지원연구원 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
WO2006052134A2 (en) 2004-11-12 2006-05-18 N.V. Nutricia Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses
JP5068174B2 (ja) 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー．ブイ． Ｄｐｐ−ｉｖを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
DE602006018856D1 (de) 2005-01-18 2011-01-27 Dsm Ip Assets Bv Neue nutrazeutika-zusammensetzungen
US8129337B2 (en) 2005-02-03 2012-03-06 Dsm Ip Assets B.V. Compositions comprising epigallocatechin gallate and protein hydrolysate
US20090123605A1 (en) 2005-02-09 2009-05-14 Wilhelmus Antonius J Van Benthum Food Products Comprising Hydrolysed Milk Solids With Improved Taste
EA200702352A1 (ru) 2005-04-28 2008-02-28 ДСМ АйПи АССЕТС Б.В. Новые композиции нутрицевтиков
WO2006114194A1 (en) 2005-04-28 2006-11-02 Unilever N.V. Peptides having a health benefit and compositions comprising them
US20090074893A1 (en) 2005-04-29 2009-03-19 Campina Nederland Holding B.V. Antiviral peptides
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
US20060286208A1 (en) * 2005-06-01 2006-12-21 Nagendra Rangavajla Methods for producing protein partial hydrolysates and infant formulas containing the same
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
CN101212911B (zh) 2005-07-01 2012-12-05 努特里希亚公司 含水解的蛋白质的婴儿营养品
GB0523806D0 (en) 2005-11-23 2006-01-04 Micromass Ltd Mass spectrometer
EP1954299B1 (en) 2005-11-30 2016-01-13 Campina Nederland Holding B.V. Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US20100167979A1 (en) 2006-02-09 2010-07-01 Calpis Co. Ltd Rheumatoid arthritis-preventive agent for oral intake
WO2007107587A2 (en) 2006-03-22 2007-09-27 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
US20090305945A1 (en) 2006-04-12 2009-12-10 Swen Wolfram Novel nutraceutical compositions
EP2039366A4 (en) 2006-04-21 2010-01-06 Meiji Seika Kaisha COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
NZ572152A (en) 2006-04-28 2012-07-27 Megmilk Snow Brand Co Ltd Peptidethat is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agen
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
WO2008015374A2 (en) 2006-08-04 2008-02-07 Shs International Ltd Protein free formula
WO2008017415A1 (en) 2006-08-09 2008-02-14 Dsm Ip Assets B.V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2008153429A2 (en) 2007-06-11 2008-12-18 Uniwersytet Jagiellonski A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
US20100204152A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of gluten exorphin c : as a therapeutic agent
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2253324A1 (en) 2009-04-30 2010-11-24 Consejo Superior De Investigaciones Cientificas Use of a casein-derived peptide and compositions thereof as antihypertensive
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
ES2524067T3 (es) 2009-12-04 2014-12-03 Mjn U.S. Holdings Llc Formulación nutricional que comprende un hidrolizado que contiene péptidos de leche de vaca y/o péptidos derivados del mismo para la inducción de tolerancia
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US20120322726A1 (en) 2010-02-24 2012-12-20 Morinaga Milk Industry Co., Ltd. Therapeutic agent for eating disorders
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
US9700071B2 (en) * 2012-03-26 2017-07-11 Axcella Health Inc. Nutritive fragments, proteins and methods

Also Published As

Publication number Publication date
WO2014150558A1 (en) 2014-09-25
PH12015502071A1 (en) 2016-01-25
TW201521603A (zh) 2015-06-16
HK1216976A1 (zh) 2016-12-16
US20140271553A1 (en) 2014-09-18
MY172218A (en) 2019-11-18
AU2014237014A1 (en) 2015-08-13
NZ710020A (en) 2020-04-24
RU2015140269A (ru) 2017-04-21
SG11201505689PA (en) 2015-08-28
AR095332A1 (es) 2015-10-07
MX2015011934A (es) 2015-12-01
CA2905799A1 (en) 2014-09-25
US20150093463A1 (en) 2015-04-02
US9457058B2 (en) 2016-10-04
AU2014237014B2 (en) 2018-02-22
PE20151978A1 (es) 2016-01-23
MX365415B (es) 2019-06-03
CN105072928B (zh) 2021-02-12
US8889633B2 (en) 2014-11-18
EP2983531A1 (en) 2016-02-17
ES2736313T3 (es) 2019-12-27
PH12015502071B1 (en) 2016-01-25
EP2983531B1 (en) 2019-04-24
CA2905799C (en) 2021-03-30
CN105072928A (zh) 2015-11-18

Similar Documents

Publication Publication Date Title
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
BR112014012808A2 (pt) proteína de fusão anticâncer
BR112017007543A2 (pt) peptídeos com propriedades anti-inflamatórias
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112012030179A2 (pt) polipeptídeo contendo fc, métodos para produzir um polipeptídeo contendo fc, para aumentar as propriedades anti-inflamatórias ou diminuir a citotoxicidade de um polipeptídeo contendo fc, e, uso do polipeptídeo contendo fc.
BR112015023447A2 (pt) purificação de proteínas helicoidais triplas
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112016013299A2 (pt) Composto
BR112015018259A2 (pt) Redução de resposta pró-inflamatória
EP3363458A3 (en) A peptide
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112015025733A2 (pt) composição compreendendo uma combinação de um ex-trato de sabugueiro e uma estirpe de lactobacillus rhamnosus
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112019009131A2 (pt) vacina contra o parvovírus suíno, o vírus da síndrome respiratória e reprodutiva dos suínos e métodos de produção das mesmas
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]